重要内容提示： 交易简要内容：华润双鹤药业股份有限公司(以下简称"公司") 拟参与设立华润医药(成都)创新投资基金合伙企业(有限合伙)(暂定名， 以工商核准名为准，以下简称"本基金"或"该基金")。该基金目标募集 规模为 10 亿元人民币，公司拟以自有资金出资 4,000 万元人民币， 占基金总出资额的 4.00%。 本次交易构成关联交易，不构成重大资产重组。 本次交易已经公司内部有权机构审议批准，无需提交董事会和 股东会审议。 过去 12 个月内，除日常关联交易外，公司与中国华润有限公 司及其控制的主体无其他交易。 截至本公告披露日，该基金尚在筹备设立过程中，合伙协议尚 未签署，基金能否成功设立、募集规模及投资进度均存在不确定性。 基金具有投资周期长、流动性较低的特点，在投资运作过程中将受到 宏观经济、行业周期、政策法规等多种因素影响，可能面临投资收益 不达预期甚至本金损失的风险。 证券代码：600062 证券简称：华润双鹤 公告编号：临 2025-060 华润双鹤药业股份有限公司 关于参与设立华润医药产业投资基金二期 暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或 ...

Group 1 - The core viewpoint of the news is that the Artemisinin concept sector has seen a significant increase, with a rise of 2.65%, ranking third among concept sectors in terms of growth [1] - Within the Artemisinin concept sector, 10 stocks experienced an increase, with Rundu Co., Ltd. hitting the daily limit, and notable gains from Fosun Pharma, China Resources Sanjiu, and Haizheng Pharmaceutical, which rose by 3.94%, 3.10%, and 2.71% respectively [1][2] - The sector attracted a net inflow of 369 million yuan from main funds, with seven stocks receiving net inflows, and five stocks seeing inflows exceeding 30 million yuan [2] Group 2 - The leading stock in terms of net inflow was Rundu Co., Ltd., which saw a net inflow of 145 million yuan, followed by Fosun Pharma, Haizheng Pharmaceutical, and Zhejiang Medicine with net inflows of 101 million yuan, 53.91 million yuan, and 50.35 million yuan respectively [2][3] - In terms of fund inflow ratios, Rundu Co., Ltd., Zhejiang Medicine, and China Resources Sanjiu had the highest ratios, with net inflow rates of 42.20%, 11.87%, and 8.44% respectively [3] - The trading performance of the top stocks in the Artemisinin concept sector showed significant turnover rates, with Rundu Co., Ltd. at 10.26%, Fosun Pharma at 2.30%, and Haizheng Pharmaceutical at 5.63% [3]

Group 1 - Lin Yanglin, the chairman of Xinlicheng, has been placed under detention and is under investigation, which may impact investor confidence despite the company stating the matter is unrelated to its operations [1] - Weiming Pharmaceutical's stock will be suspended for one day due to its trial progress not meeting expectations and its subsidiary's inability to resume normal operations within three months, affecting performance expectations [2] - Tengsheng Bo Pharmaceutical has signed a licensing agreement with Health Yuan Group for the exclusive rights to research, develop, and commercialize BRII-693 in China, providing cash flow and enhancing market expectations [3] Group 2 - China Resources Double Crane announced a cash dividend of 3.71 yuan per 10 shares despite a decline in revenue and net profit, indicating strong cash flow and commitment to shareholders [4] - InnoTech's subsidiary has obtained long-term product certification for a flu detection kit, which is expected to enhance market competitiveness and potentially increase revenue [5]

Core Points - The company announced a cash dividend of 0.371 CNY per share for A shares, approved at the 2024 annual shareholders' meeting on May 16, 2025 [1] - The record date for the dividend is July 10, 2025, with the ex-dividend date and payment date both set for July 11, 2025 [1] Dividend Distribution Details - The total number of shares for the dividend distribution is based on the company's total share capital of 1,038,836,522 shares [1] - The cash dividend will be distributed to shareholders registered with China Securities Depository and Clearing Corporation Limited, Shanghai Branch, after the market closes on the record date [1] - Shareholders who have not completed designated trading will have their dividends held by the clearing company until they complete the necessary procedures [1] Taxation Information - For individual shareholders holding shares for over one year, the dividend income is temporarily exempt from personal income tax, resulting in a net cash dividend of 0.371 CNY per share [2][3] - For shares held for one year or less, the company will not withhold personal income tax at the time of distribution; tax will be calculated upon the transfer of shares [2] - Qualified Foreign Institutional Investors (QFII) will have a 10% corporate income tax withheld, resulting in a net cash dividend of 0.3339 CNY per share [4] - Hong Kong investors through the Stock Connect will also have a 10% tax withheld, leading to the same net cash dividend of 0.3339 CNY per share [4] - Other institutional investors will receive the gross dividend of 0.371 CNY per share without tax withholding [5]

华润双鹤药业股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 证券代码：600062 证券简称：华润双鹤 公告编号：临 2025-059 重要内容提示： 每股分配比例 A 股每股现金红利0.371元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权(息)日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/7/10 | － | 2025/7/11 | 2025/7/11 | 差异化分红送转：否 一、通过分配方案的股东会届次和日期 本次利润分配方案经公司2025 年 5 月 16 日的2024年度股东会审 议通过。 二、分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结 算有限责任公司上海分公司(以下简称"中国结算上海分公司")登记 在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本1,038,836,522股为基 ...

Group 1 - The Artemisinin concept index increased by 0.65%, ranking 10th among concept sectors, with four stocks rising, including Haizheng Pharmaceutical which hit the daily limit, and Zhejiang Medicine, Huaren Shuanghe, and Baiyunshan also showing gains of 0.79%, 0.69%, and 0.08% respectively [1] - The leading decliners in the sector included Rundu Co., New Harmony, and Kunming Pharmaceutical, which fell by 1.41%, 1.36%, and 1.17% respectively [1] - The net inflow of main funds into the Artemisinin concept sector was 95 million yuan, with Haizheng Pharmaceutical receiving the highest net inflow of 105 million yuan, followed by Zhejiang Medicine, New Harmony, and Baihua Pharmaceutical with net inflows of 25.71 million yuan, 9.91 million yuan, and 2.14 million yuan respectively [2][3] Group 2 - In terms of fund inflow ratios, Haizheng Pharmaceutical, Zhejiang Medicine, and Baihua Pharmaceutical had the highest net inflow rates of 9.03%, 5.48%, and 2.27% respectively [3] - The trading performance of key stocks in the Artemisinin concept included Haizheng Pharmaceutical with a daily increase of 10.02% and a turnover rate of 9.22%, while Zhejiang Medicine rose by 0.79% with a turnover rate of 3.19% [3][4] - Other stocks such as New Harmony and Baihua Pharmaceutical experienced declines of 1.36% and 0.41% respectively, with turnover rates of 1.04% and 3.34% [3][4]

Group 1 - Guizhou Moutai has repurchased a total of 3.3821 million shares as of June 30, 2025, accounting for 0.2692% of the total share capital, with a total expenditure of 5.202 billion yuan [2] - Luxshare Precision is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global financing capabilities and governance transparency [2] - Huazhong Xinchuang has received a project notification from a leading domestic eVTOL manufacturer for the development and supply of an intelligent cockpit multimedia display system [3] Group 2 - Meinohua expects a net profit of 46 million to 52 million yuan for the first half of 2025, representing a year-on-year increase of 142.84% to 174.52% [4] - Jiangnan Water has received a report from shareholder Lianan Life Insurance indicating an increase in shareholding by 46.99 million shares, representing 5.03% of the total share capital [5] - Huasen Pharmaceutical has received approval for clinical trials of its CX001 sustained-release tablets, marking a milestone for its innovative drug development platform [6] Group 3 - Zongshen Power anticipates a net profit growth of 70% to 100% for the first half of the year [7] - Yutong Bus reported a sales volume of 5,919 units in June, a year-on-year increase of 24.79% [7] - Guangzhou Port expects a 7.0% year-on-year increase in container throughput for June 2025 [7] Group 4 - Data Port's shareholders plan to reduce their holdings by up to 1.74% and 0.26% of the company's shares [9] - Humanwell Healthcare's shareholder plans to increase its stake by 1% to 2% [9] - Nengte Technology plans to repurchase shares worth between 300 million to 500 million yuan [10]

J002适用于干眼的治疗。 该药品由华润紫竹和温州医科大学联合开发，华润紫竹于2025 年4月9日向国家药监局提交临床默示许可申请，于2025年4月16日获 得受理通知书，并于2025年6月27日获得《药物临床试验批准通知书》。 证券代码：600062 证券简称：华润双鹤 公告编号：临 2025－058 华润双鹤药业股份有限公司 关于全资子公司华润紫竹药业有限公司 J002获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 近日，华润双鹤药业股份有限公司(以下简称"公司")全资子公司 华润紫竹药业有限公司(以下简称"华润紫竹")收到了国家药品监督管 理局(以下简称"国家药监局")颁发的J002(以下简称"该药品")《药物临 床试验批准通知书》(编号：2025LP01661、2025LP01662)。现将相关 情况公告如下： | 药品名称 | | J002 | | --- | --- | --- | | 注册分类 | | 治疗用生物制品 1 类 | | 受 理 | 号 | CXSL2500314、 ...

证券代码：600062 证券简称：华润双鹤 公告编号：临 2025-057 华润双鹤药业股份有限公司 关于复方氨基酸注射液(18AA-Ⅸ)获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 近日，华润双鹤药业股份有限公司(以下简称"华润双鹤"或"公 司")收到了国家药品监督管理局(以下简称"国家药监局")颁发的复 方氨基酸注射液(18AA-Ⅸ)(以下简称"该药品")《药品注册证书》(编 号：2025S01935)。现将相关情况公告如下： | | 药品通用名称：复方氨基酸注射液(18AA-Ⅸ) | | --- | --- | | 药品名称 英 文 | 名 拉 丁 名 ： / Compound Amino Acids | | | Injection(18AA-Ⅸ) | | 剂型 注射剂 | | | 注册分类 化学药品 | 类 4 | | 规格 | 200ml:12.250g(按总氨基酸计) | | 药品批准文号 国药准字 | H20254653 | | 申请事项 | 药品注册(境内生产) | | 审批结论 | ...

Core Viewpoint - China Resources Double Crane (华润双鹤) has received the drug registration certificate for Compound Amino Acid Injection (18AA-Ⅸ) from the National Medical Products Administration, indicating a significant step in the company's product development and market entry strategy [1] Group 1: Product Development - The company initiated the research and development of the Compound Amino Acid Injection (18AA-Ⅸ) in October 2022 and submitted the application for market approval on October 20, 2023, which was accepted on October 27, 2023 [1] - The expected approval date for the product is June 24, 2025, highlighting the timeline for market entry [1] - The total R&D investment for this product has reached 10.7435 million yuan [1] Group 2: Market Potential - The global sales figure for "Neoamiyu" in 2023 is reported to be 32.2056 million USD, indicating a substantial market presence [1] - In the domestic market, the total sales for Compound Amino Acid Injection (18AA-Ⅸ) are projected to be 120 million yuan in 2024, with Guangzhou Green Cross Pharmaceutical Co., Ltd. holding a 100% market share [1]